Nuclear survivin is associated with cell proliferative advantage in uterine cervical carcinomas during radiation therapy

Journal of Clinical Pathology

Volumn 65, Issue 5, 2012, Pages 424-430

  Chaopotong, Pattama ^a   Kajita, Sabine ^a   Hashimura, Miki ^a   Saegusa, Makoto ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; SURVIVIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DISEASE ASSOCIATION; EXON; FEMALE; GENETIC VARIABILITY; HUMAN; HUMAN CELL; LABELING INDEX; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIATION DOSE; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ALTERNATIVE SPLICING; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL NUCLEUS; CELL PROLIFERATION; DNA, NEOPLASM; FEMALE; GENE EXPRESSION; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MIDDLE AGED; PROTEIN ISOFORMS; TUMOR MARKERS, BIOLOGICAL; UBIQUITIN-PROTEIN LIGASES; UTERINE CERVICAL NEOPLASMS;

EID: 84860754164     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2011-200477     Document Type: Article

References (27)

1. GLOBOCAN 2008 Country Fast Stat. http://globocan.iarc.fr
2. Fulda S, Debatin KM. Apoptosis signaling in tumor therapy. Ann NY Acad Sci 2004;1028:150-6. (Pubitemid 40361819)
3. Paxton JR, Bolger BS, Armour A, et al. Apoptosis in cervical squamous carcinoma: predictive value for survival following radiotherapy. J Clin Pathol 2000;53:197-200. (Pubitemid 30163602)
4. Brown DC, Cole D, Gatter KC, et al. Carcinoma of the cervix uteri: an assessment of tumor proliferation using the monoclonal antibody Ki67. Br J Cancer 1988;57:178-81. (Pubitemid 18085400)
5. Suzuki M, Tsukagoshi S, Saga Y, et al. Assessment of proliferation index with MIB-1 as a prognostic factor in radiation therapy for cervical cancer. Gynecol Oncol 2000;79:300-4.
6. Stauber RH, Mann W, Knauer SK. Nuclear and cytoplasmic survivin: molecular mechanism, prognostic, and therapeutic potential. Cancer Res 2007;67:5999-6002. (Pubitemid 47037475)
7. Li F. Role of survivin and its splice variants in tumorigenesis. Br J Cancer 2005;92:212-16. (Pubitemid 40343130)
8. Frost M, Jarboe EA, Orlicky D, et al. Immunohistochemical localization of survivin in benign cervical mucosa, cervical dysplasia, and invasive squamous cell carcinoma. Am J Clin Pathol 2002;117:738-44. (Pubitemid 34457008)
9. Shimosato Y, Oboshi S, Baba K. Histological evaluation of effects of radiotherapy and chemotherapy for carcinomas. Jpn J Clin Oncol 1971;1:19-35.
10. Kerr JF, Winterford CM, Harmon BV. Apoptosis: its significance in cancer and cancer therapy. Cancer 1994;73:2013-26. (Pubitemid 24107952)
11. Badran A, Yoshida A, Ishikawa K, et al. Identification of a novel splice variant of the human anti-apoptosis gene survivin. Biochem Biophys Res Commun 2004;314:902-7. (Pubitemid 38112885)
12. Saegusa M, Hashimura M, Kuwata T, et al. Requirement of the AKT/β-catenin pathway for uterine carcinosarcoma genesis, modulating E-cadherin expression through the transactivation of slug. Am J Pathol 2009;174:2107-15.
13. Saegusa M, Kamata Y, Isono M, et al. Bc-2 expression is correlated with a low apoptotic index and associated with progesterone receptor immunoreactivity in endometrial carcinomas. J Pathol 1996;180:275-82. (Pubitemid 26393676)
14. Koshida Y, Saegusa M, Okayasu I. Apoptosis, cell proliferation and expression of Bcl-2 and Bax in gastric carcinomas: immunohistochemical and clinicopathological study. Br J Cancer 1997;75:367-73. (Pubitemid 27051051)
15. Li F, Ackermann EJ, Bennett CF, et al. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1999;1:461-6. (Pubitemid 129503664)
16. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998;396:580-4. (Pubitemid 28563719)
17. Yamamoto H, Ngan CY, Monden M. Cancer cells survive with survivin. Cancer Sci 2008;99:1709-14.
18. Havre PA, Yuan J, Hedrick L, et al. p53 inactivation by HPV16 E6 results in increased mutagenesis in human cells. Cancer Res 1995;55:4420-4.
19. Kamradt MC, Mohideen N, Krueger E, et al. Inhibition of radiation-induced apoptosis by dexamethasone in cervical carcinoma cell lines depends upon increased HPV E6/E7. Br J Cancer 2000;82:1709-16. (Pubitemid 30229583)
20. Kilic G, Cardillo M, Ozdemirli M, et al. Human papillomavirus 18 oncoproteins E6 and E7 enhance irradiation- and chemotherapeutic agent-induced apoptosis in p53 and Rb mutated cervical cancer cell lines. Eur J Gynaecol Oncol 1999;20:167-71. (Pubitemid 29286480)
21. Chandele A, Prasad V, Jagtap JC, et al. Upregulation of survivin in G2/M cells and inhibition of caspase 9 activity enhance resistance in staurosporine-induced apoptosis. Neoplasia 2004;6:29-40. (Pubitemid 38391947)
22. Shin S, Sung BJ, Cho YS, et al. An antiapoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 2001;40:1117-23. (Pubitemid 32108606)
23. Rodriguez JA, Span SW, Ferreira CG, et al. CRM1-mediated nuclear export determines the cytoplasmic localization of the antiapoptotic protein survivin. Exp Cell Res 2002;275:44-53.
24. Ryan B, O'Donovan N, Browne B, et al. Expression of survivin and its splice variants survivin-2B and survivin-deltaEX3 in breast cancer. Br J Cancer 2005;92:120-4. (Pubitemid 40188444)
25. Sampath J, Pelus LM. Alternative splice variants of survivin as potential targets in cancer. Curr Drug Discov Technol 2007;4:174-91. (Pubitemid 350171819)
26. Muchmore SW, Chen J, Jakob C, et al. Crystal structure and mutagenic analysis of the inhibitor-of-apoptosis protein survivin. Mol Cell 2000;6:173-82.
27. Chantalat L, Skoufias DA, Kleman JP, et al. Crystal structure of human survivin reveals a bow tie-shaped dimer with two unusual alpha-helical extensions. Mol Cell 2000;6:183-9.